Form 4: Capricor Therapeutics Director Frank Litvack Reports Stock Option Grant and Holdings

Frank Litvack, a director at Capricor Therapeutics, reported the acquisition of stock options and adjustments to his holdings of common stock.

Summary

• Frank Litvack, a director at Capricor Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report includes the grant of 50,000 stock options exercisable at $14.96 per share, vesting monthly starting February 1, 2025, and expiring on January 2, 2035.
• Litvack's direct holdings of common stock are reported as 107,382 shares, adjusted to correct a prior miscalculation.
• He also holds 46,278 shares indirectly through a family trust where he serves as trustee.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of insider transactions, which is generally neutral. The stock option grant is a positive sign of alignment with the company's interests.

Positives

• The grant of stock options to a director aligns their interests with the company's performance and shareholder value.
• The vesting schedule of the stock options encourages long-term commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies to incentivize performance and align interests with shareholders.
• The vesting schedule of the options is typical, with monthly vesting over a period of time.

Stakeholder Impact

• The stock option grant to a director can be seen as a positive sign by shareholders, indicating alignment of interests.
• The disclosure provides transparency to the market regarding insider holdings.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Director, Capricor Therapeutics, CAPR, Equity Securities, Frank Litvack